Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:4.1.2.13 (
aldolase
)
3,461
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Mammalian phospholipase D (PLD) has been implicated in the cellular signal transduction pathways leading to diverse physiological events and known to be regulated by many cellular factors. To identify the proteins that interact with PLD, we performed a protein overlay assay with fractions obtained from the sequential column chromatographic separation of rat brain cytosol using purified
PLD2
as a probe. A protein of molecular mass 40 kDa, which was detected by anti-PLD antibody with overlaying of the purified
PLD2
, is shown to be aldolase C by peptide-mass fingerprinting with matrix-assisted laser desorption/ionization-time-of flight mass spectrometry (MALDI-TOF-MS). Aldolase A also showed similar binding properties as aldolase C and was co-immunoprecipitated with
PLD2
in COS-7 cells overexpressing
PLD2
and aldolase A. The PH domain corresponding to amino acids 201-310 of
PLD2
was necessary for the interaction observed in vitro, and aldolase A was found to interact with the PH domain of
PLD2
specifically, but not with other PH domains.
PLD2
activity was inhibited by the presence of purified aldolase A in a dose-dependent manner, and the inhibition by 50% was observed by the addition of less than micromolar aldolase A. Moreover, the inclusion of the
aldolase
metabolites fructose 1,6-bisphosphate (F-1,6-P) or glyceraldehyde 3-phosphate (G-3-P) resulted in an enhanced interaction between
PLD2
and aldolase A with a concomitant increase in the potential ability of aldolase A to inhibit
PLD2
, which suggests the existence of a possible regulation of the interaction by the change of intracellular concentrations of glycolytic metabolites.
...
PMID:Phospholipase D2 directly interacts with aldolase via Its PH domain. 1187 50